- Home
- MRNA vs ALLY Comparison
MRNA vs ALLY Comparison
Compare MRNA & ALLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRNA
- ALLY
- Stock Information
- Founded
- MRNA 2010
- ALLY 1919
- Country
- MRNA United States
- ALLY United States
- Employees
- MRNA N/A
- ALLY N/A
- Industry
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- ALLY Major Banks
- Sector
- MRNA Health Care
- ALLY Finance
- Exchange
- MRNA Nasdaq
- ALLY Nasdaq
- Market Cap
- MRNA 10.9B
- ALLY 12.0B
- IPO Year
- MRNA 2018
- ALLY 2014
- Fundamental
- Price
- MRNA $25.87
- ALLY $44.37
- Analyst Decision
- MRNA Hold
- ALLY Buy
- Analyst Count
- MRNA 19
- ALLY 18
- Target Price
- MRNA $43.50
- ALLY $45.07
- AVG Volume (30 Days)
- MRNA 12.2M
- ALLY 2.6M
- Earning Date
- MRNA 11-06-2025
- ALLY 10-17-2025
- Dividend Yield
- MRNA N/A
- ALLY 2.73%
- EPS Growth
- MRNA N/A
- ALLY N/A
- EPS
- MRNA N/A
- ALLY 1.04
- Revenue
- MRNA $3,078,000,000.00
- ALLY $6,852,000,000.00
- Revenue This Year
- MRNA N/A
- ALLY $19.77
- Revenue Next Year
- MRNA $10.17
- ALLY $14.41
- P/E Ratio
- MRNA N/A
- ALLY $42.40
- Revenue Growth
- MRNA N/A
- ALLY 1.11
- 52 Week Low
- MRNA $23.15
- ALLY $29.52
- 52 Week High
- MRNA $75.37
- ALLY $44.71
- Technical
- Relative Strength Index (RSI)
- MRNA 51.44
- ALLY 81.00
- Support Level
- MRNA $23.18
- ALLY $40.83
- Resistance Level
- MRNA $25.90
- ALLY $44.71
- Average True Range (ATR)
- MRNA 1.16
- ALLY 0.84
- MACD
- MRNA 0.27
- ALLY 0.25
- Stochastic Oscillator
- MRNA 95.05
- ALLY 90.69
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
About ALLY Ally Financial Inc.
Formerly the captive financial arm of General Motors, Ally Financial became an independent publicly traded firm in 2014 and is one of the largest consumer auto lenders in the country. While the firm has expanded its product offerings over time, it remains primarily focused on auto lending, with more than 70% of its loan book in consumer auto loans and dealer financing. Ally also offers auto insurance, commercial loans, credit cards, and holds a portfolio of mortgage debt, giving the bank a diversified business model, which includes brokerage services.